---
schema_version: "secwatch.filing_event.v1"
accession: "0001490978-24-000087"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:46:42.738579+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Schrödinger enters $2.272B collaboration with Novartis; $150M upfront

## Summary
- Upfront payment of $150 million to be paid after HSR waiting period expires.
- Eligible for up to $892M in discovery/development milestones and $1.38B in commercial milestones across initial project plans.
- Eligible for tiered royalties on net sales of collaboration products: mid-single-digit to low-double-digit percent, subject to reductions.
- Research term for each project plan is generally four years; Novartis responsible for clinical development and commercialization.
- Exclusivity provisions prevent Schrödinger from working on collaboration targets with third parties for specified period.

## SEC filing metadata
- accession: 0001490978-24-000087
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000149097824000087/0001490978-24-000087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000149097824000087/sdgr-20241111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001490978-24-000087
- JSON: https://secwatch.observer/filing/0001490978-24-000087.json
- Plain text: https://secwatch.observer/filing/0001490978-24-000087.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.